Adamis Konstantinos S, Georgoulakis Michail, Angelonidis Ioannis, Korovesis Dimitris, Papadopoulos Christos, Kapsalis Michael, Tavernarakis Nektarios, Eleftheriadis Nikolaos, Neochoritis Constantinos G
Department of Chemistry, University of Crete, Voutes, Heraklion, Greece.
Foundation for Research and Technology Hellas, Institute of Molecular Biology and Biotechnology, Heraklion, Greece.
Chemistry. 2025 Jun 17;31(34):e202501513. doi: 10.1002/chem.202501513. Epub 2025 May 13.
Recent advances in drug discovery and development have been marked by the emergence of new modalities, including small molecule theranostic agents. While initial results from clinical trials have been promising, modern detectable inhibitors are still in an early stage of development. In this study, we present a strategy for chemically evolving a fluorescent imaging agent into a potent therapeutic entity, which not only retains its properties but also enhances its inhibition and detection applicability. By utilizing 15-LOX-1 as a model system, we leverage prior knowledge of its inhibitors to rationally functionalize fluorescein, enabling the targeted and highly efficient synthesis of over 20 derivatives across four different scaffolds. This approach ultimately led to the development of a potent, cell-permeable inhibitor that effectively engages its target in live cells and enables real-time visualization. These findings validate our new strategy for the development of small molecule diagnostic modulators, paving the way for application in other targets as well.
药物发现与开发的最新进展以新的模式出现为标志,包括小分子诊疗剂。虽然临床试验的初步结果很有前景,但现代可检测抑制剂仍处于开发的早期阶段。在本研究中,我们提出了一种将荧光成像剂化学演变成强效治疗实体的策略,该实体不仅保留其特性,还增强其抑制和检测适用性。通过利用15-脂氧合酶-1作为模型系统,我们利用其抑制剂的先验知识对荧光素进行合理功能化,从而能够在四种不同支架上靶向且高效地合成20多种衍生物。这种方法最终导致开发出一种强效的、可穿透细胞的抑制剂,该抑制剂能在活细胞中有效作用于其靶点并实现实时可视化。这些发现验证了我们开发小分子诊断调节剂的新策略,也为在其他靶点上的应用铺平了道路。